Sygnature Discovery

Sygnature Discovery is a leading ‘centre of excellence’ for integrated drug discovery, offering significant know-how and expertise across a broad range of therapeutic areas and biological target classes.

More than 80% of Sygnature’s scientists possess a PhD and 40% have been recruited from outside of the UK. Many of Sygnature’s research scientists bring considerable pharmaceutical industry drug discovery experience which is applied to every research project we undertake for our clients.

Sygnature Discovery’s dynamic blend of youth and experience in our research scientists is further enhanced through our unique approach to laboratory working – Sygnature’s medicinal chemists, in vitro biologists and DMPK scientists, are co-located on the same research site in the same laboratories to efficiently advance our clients’ drug discovery projects into pre-clinical development. This synergistic approach to drug discovery has delivered an admirable track record of success with more than 20 clinical candidates being delivered to our clients since 2011.

Key areas of expertise include oncology and immuno-oncology, neuroscience, inflammation and immunology, metabolic diseases, anti-infectives, orphan indications and respiratory disorders, across a broad range of therapeutic targets, including GPCRs, nuclear hormone receptors, kinases, epigenetic, ion channels, proteases and protein–protein interactions.